Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by stefchillon May 08, 2018 8:07pm
74 Views
Post# 28001419

FDA chief moves to promote artificial intelligence in health

FDA chief moves to promote artificial intelligence in healthGood read...

FDA chief moves to promote artificial intelligence in health care

FDA chief moves to promote artificial intelligence in health care

The Food and Drug Administration (FDA) is moving to encourage the use of artificial intelligence (AI) in health care, the agency's chief said Thursday. 

"AI holds enormous promise for the future of medicine," FDA Commissioner Scott Gottlieb said in prepared remarks to the Health Datapalooza conference in Washington, D.C. 

He said the FDA is working on an updated "new regulatory framework" that will allow regulators to keep up with new technology and "promote innovation in this space."

"We expect to see an increasing number of AI-based submissions in the coming years, starting with medical imaging devices, and we're working with experts in the field," he said. 


As an example of the new health technology he is seeking to promote, Gottlieb pointed to a new medical device approved by the FDA earlier this month that uses artificial intelligence and a special camera to help diagnose a condition in people with diabetes known as retinopathy that can lead to vision loss. 

He said the FDA is working with experts to update the way it evaluates these new technologies in the approval process. 

 

"Eventually, AI tools could be integrated directly into smartphones or wearable devices for a variety of early detection applications, reducing the need for expensive specialist visits while increasing the likelihood that we're catching potentially serious problems early," Gottlieb added. "These are no longer far-fetched ideas."

Bullboard Posts